

Resource Summary Report

Generated by [dkNET](#) on Sep 11, 2026

OncoKB

RRID:SCR_014782

Type: Tool

Proper Citation

OncoKB (RRID:SCR_014782)

Resource Information

URL: <http://oncokb.org>

Proper Citation: OncoKB (RRID:SCR_014782)

Description: Precision oncology knowledge base which contains information about the effects and treatment implications of specific cancer gene alterations. OncoKB contains detailed information about specific alterations in 418 cancer genes. Each variant entry contains biological effect, prevalence, prognostic information, and treatment implications. Information is curated from various sources, such as guidelines from the FDA, ClinicalTrials.gov, and scientific literature by a network of clinical fellows, research fellows, and faculty members at Memorial Sloan Kettering Cancer Center.

Resource Type: data or information resource, database, portal

Keywords: oncology, knowledge base, cancer, cancer gene, gene alteration, curation, somatic mutation, FASEB list

Related Condition: Cancer

Availability: Public

Resource Name: OncoKB

Resource ID: SCR_014782

License URLs: <http://oncokb.org/#!/terms>

Record Creation Time: 20220129T080322+0000

Record Last Update: 20260905T133049+0000

Ratings and Alerts

No rating or validation information has been found for OncoKB.

No alerts have been found for OncoKB.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 988 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kojima M, et al. (2026) Precision Oncology for Pediatric Solid Tumors Using In-Hospital Pediatric/AYA Malignancy-Specific Panel Sequencing. *Cancer science*, 117(3), 797.

Buckley KH, et al. (2026) Gastric Epithelium from BRCA1 and BRCA2 Carriers Harbors Increased Double-Stranded DNA Damage and Enhanced Growth Potential. *Molecular cancer research : MCR*, 24(7), 589.

van der Elst A, et al. (2026) Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(13), 2732.

Meng X, et al. (2026) TE-SCALE: a comprehensive database for exploring transposable element expression across human cancers at single-cell resolution. *Nucleic acids research*, 54(D1), D1658.

ElHarouni D, et al. (2026) Integrative Multiomics and Drug Sensitivity Profiling Reveal Potential Biomarkers and Therapeutic Strategies in Pediatric Solid Tumors. *Cancer research*, 86(3), 773.

Shiozaki M, et al. (2026) Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Nonmuscular-Invasive Urothelial Bladder Cancer. *International journal of urology : official journal of the Japanese Urological Association*, 33(1), e70293.

Pu Y, et al. (2026) DNA methyltransferase inhibition is a therapeutic vulnerability in VHL-deficient renal cell carcinoma cells. *Experimental & molecular medicine*, 58(3), 798.

Dobri? N, et al. (2026) Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria. *ESMO open*, 11(4), 106939.

Kert Š, et al. (2026) Identification and prioritisation of tumour antigen candidates from 79 glioblastoma transcriptomes. *Cancer immunology, immunotherapy : CII*, 75(5).

Zhang J, et al. (2026) Prognostic and therapeutic roles of specific genotypes through target-gene sequencing on gastroenteropancreatic neuroendocrine carcinoma. *The*

oncologist, 31(6).

Hessey S, et al. (2026) Evolutionary characterization of lung cancer metastasis. *Nature*, 653(8115), 911.

Brunet A, et al. (2026) Immune landscape characterization of neurofibromas with atypical features in Neurofibromatosis1 reveals PD-1 and the Tim-3/Galectin-9 pathway as potential therapeutic targets. *Acta neuropathologica communications*, 14(1).

Wu Y, et al. (2026) Comprehensive molecular characterization identifies therapeutic vulnerabilities in ovarian clear cell carcinoma. *Genome medicine*, 18(1).

Carta MG, et al. (2026) Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology. *The Journal of molecular diagnostics : JMD*, 28(6), 469.

Rony R, et al. (2026) Putative breast cancer risk variants from populations of South Asian ancestry are under-represented in public variant classification databases. *Breast cancer research : BCR*, 28(1), 5.

Lim S, et al. (2026) Development and Performance Validation of a Comprehensive Liquid Biopsy Genotyping Panel for Pan-cancer Analysis. *Annals of laboratory medicine*, 46(2), 210.

Müller DC, et al. (2026) Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer. *Nature communications*, 17(1).

La Porte P, et al. (2026) Unique Features of a Comprehensive Genomic Profiling Panel: Expanding Treatment Options in a Value-Based Community Oncology Network. *JCO precision oncology*, 10(3), e2500623.

Siddalingappa R, et al. (2026) Precision Medicine Gene Network Analyser: part I-cancer driver gene identification through network topology and ensemble machine learning. *Genomics & informatics*, 24(1).

García-Ayala FD, et al. (2026) Molecular Characterization of TP53 Variants in Exons 4-8 and p53 Immunoexpression in a Mexican Colorectal Cancer Cohort. *Cancers*, 18(11).